"We believe FGFR3 is the right target for achondroplasia, with almost one hundred percent of cases being driven by a specific mutation in the FGFR3 gene. TYRA-300 has the potential to precisely ...

The oral FGFR1-3 selective tyrosine kinase inhibitor infigratinib was found to be safe and effective at the highest studied ...

ABOUT Achondroplasia Achondroplasia is disease in which a genetic mutation of the fibroblast growth factor receptor type 3 (FGFR3) causes FGFR3 to be activated, resulting in an excessive influx of ...

Overexpression of fibroblast growth factor receptor 3 (FGFR3) has been shown to drive oncogenesis in a subset of patients with multiple myeloma. However, epithelial cancers — such as bladder ...

Achondroplasia is a rare genetic disorder of bone growth that causes short-limbed dwarfism. It occurs due to mutations in a single gene called the FGFR3.

BridgeBio (BBIO) announced that 18-month results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with ...

In September 2024, a manuscript titled "Discovery of TYRA-300: First oral selective FGFR3 inhibitor for the treatment of urothelial cancers and achondroplasia" was published in the Journal of ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...